Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALBERT L TYDINGS

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecology

NPI
1952364705
CMS profile
361673
Location
COVINGTON, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$769.95

43 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $656.61 41
Education $113.34 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALBERT L TYDINGS

NPI 1952364705 · CMS profile ID 361673

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecology

COVINGTON, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952364705?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALBERT L TYDINGS, NPI 1952364705, CMS profile ID 361673. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952364705?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ALBERT L TYDINGS, NPI 1952364705, CMS profile ID 361673. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952364705?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ALBERT L TYDINGS, NPI 1952364705, CMS profile ID 361673, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1952364705?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

43 matching records · $769.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 43 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–43 of 43.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Evofem Biosciences, Inc. $13.1312/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 976102125 CMS
MAYNE PHARMA COMMERCIAL LLC $6.4612/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821431 CMS
AbbVie Inc. $15.2011/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999344703 CMS
AbbVie Inc. $33.8411/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999344699 CMS
Astellas Pharma US Inc $20.4011/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034702341 CMS
MAYNE PHARMA COMMERCIAL LLC $23.3711/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821433 CMS
MAYNE PHARMA COMMERCIAL LLC $7.4111/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821427 CMS
AbbVie Inc. $13.7510/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999344693 CMS
MAYNE PHARMA COMMERCIAL LLC $26.5110/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821435 CMS
Astellas Pharma US Inc $17.7910/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034604575 CMS
MAYNE PHARMA COMMERCIAL LLC $6.6810/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821429 CMS
ASCEND THERAPEUTICS US, LLC $24.4409/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054394933 CMS
AbbVie Inc. $13.1609/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999344687 CMS
Hologic Sales and Service, LLC $15.9209/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024810139 CMS
MAYNE PHARMA COMMERCIAL LLC $23.5108/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821437 CMS
Evofem Biosciences, Inc. $13.0708/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 976102129 CMS
ASCEND THERAPEUTICS US, LLC $22.2308/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054392987 CMS
MAYNE PHARMA COMMERCIAL LLC $7.6608/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821439 CMS
AbbVie Inc. $16.2008/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999344681 CMS
AbbVie Inc. $12.1107/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999344675 CMS
MAYNE PHARMA COMMERCIAL LLC $6.8906/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821415 CMS
Astellas Pharma US Inc $11.1206/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034164305 CMS
MAYNE PHARMA COMMERCIAL LLC $1.9406/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821413 CMS
AbbVie Inc. $15.0906/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999344669 CMS
MAYNE PHARMA COMMERCIAL LLC $19.5006/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821417 CMS
AbbVie Inc. $14.5405/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999344663 CMS
Avion Pharmaceuticals $15.9605/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032959739 CMS
Hologic Sales and Service, LLC $16.1005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024810009 CMS
MAYNE PHARMA COMMERCIAL LLC $9.0905/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821411 CMS
Agile Therapeutics, Inc. $24.1605/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051459503 CMS
Organon LLC $22.5305/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046952089 CMS
MILLICENT US INC $20.0605/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027056877 CMS
MILLICENT US INC $13.3505/02/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027056881 CMS
Bayer Healthcare Pharmaceuticals Inc. $12.8604/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000781585 CMS
MAYNE PHARMA COMMERCIAL LLC $21.5004/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821425 CMS
AbbVie Inc. $14.7803/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999344657 CMS
Astellas Pharma US Inc $99.9903/14/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033972795 CMS
Astellas Pharma US Inc $23.4103/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033951579 CMS
Avion Pharmaceuticals $21.7303/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032959747 CMS
MAYNE PHARMA COMMERCIAL LLC $19.3602/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821423 CMS
MAYNE PHARMA COMMERCIAL LLC $2.6101/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821419 CMS
MAYNE PHARMA COMMERCIAL LLC $16.1001/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060821421 CMS
AbbVie Inc. $14.4401/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999344651 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $256.51 16
PY2020 $375.64 24
PY2021 $730.38 40
PY2022 $1,123.53 57
PY2023 $769.95 43
PY2024 $478.12 28
PY2025 $912.09 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $174,703.18 54
PY2024 Principal investigator $223,687.95 32
PY2023 Principal investigator $466,935.12 58
PY2022 Principal investigator $46,247.57 25
PY2021 Principal investigator $39,641.29 31
PY2020 Principal investigator $103,836.90 24
PY2019 Principal investigator $79,649.33 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Myovant Sciences Inc. $525.02 11/09/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
SPIRIT EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN No dispute reported 06/30/2026 835053719
Principal investigator 1 Myovant Sciences Inc. $1,937.81 10/13/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
SPIRIT EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN No dispute reported 06/30/2026 835053675
Principal investigator 1 Myovant Sciences Inc. $1,683.90 09/29/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
AN INTERNATIONAL PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY OF RELUGOLIX WITH ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS No dispute reported 06/30/2026 835053563
Principal investigator 1 Exeltis, USA Inc. $1,692.90 09/08/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964382821
Principal investigator 1 Myovant Sciences Inc. $2,330.08 08/18/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
SPIRIT EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN No dispute reported 06/30/2026 835053503
Principal investigator 1 Exeltis, USA Inc. $50.00 08/04/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964383123
Principal investigator 1 Exeltis, USA Inc. $1,467.90 08/03/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964383995
Principal investigator 1 Myovant Sciences Inc. $950.00 08/03/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
AN INTERNATIONAL PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY OF RELUGOLIX WITH ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS No dispute reported 06/30/2026 835053377
Principal investigator 1 Myovant Sciences Inc. $726.53 07/12/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
SPIRIT EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN No dispute reported 06/30/2026 835053341
Principal investigator 1 Exeltis, USA Inc. $200.00 07/07/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964383991
Principal investigator 1 ABBVIE INC. $696.00 07/06/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792466495
Principal investigator 1 Exeltis, USA Inc. $100.00 06/08/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964382819
Principal investigator 1 ABBVIE INC. $1,040.00 05/19/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome No dispute reported 06/30/2026 792458283
Principal investigator 1 Exeltis, USA Inc. $50.00 05/08/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964383121
Principal investigator 1 Exeltis, USA Inc. $1,800.00 05/07/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964383019
Principal investigator 1 ABBVIE INC. $1,601.95 05/06/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792454313
Principal investigator 1 Exeltis, USA Inc. $150.00 04/10/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964382823
Principal investigator 1 Exeltis, USA Inc. $1,800.00 04/09/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964383343
Principal investigator 1 ABBVIE INC. $5,021.75 04/05/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792442277
Principal investigator 1 ABBVIE INC. $840.95 03/08/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792432167
Principal investigator 1 Exeltis, USA Inc. $100.00 03/02/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964383339
Principal investigator 1 Exeltis, USA Inc. $2,502.90 03/01/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964383997
Principal investigator 1 MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. $4,201.11 02/17/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF MT-2990 IN WOMEN WITH ENDOMETRIOSIS EXPERIENCING ENDOMETRIAL RELATED PAIN No dispute reported 06/30/2026 839694469
Principal investigator 1 Myovant Sciences Inc. $797.40 02/17/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
AN INTERNATIONAL PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY OF RELUGOLIX WITH ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS No dispute reported 06/30/2026 835053037
Principal investigator 1 Myovant Sciences Inc. $1,375.91 02/12/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
LIBERTY EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, LONG-TERM EFFICACY AND SAFETY EXTENSION STUDY TO EVALUATE RELUGOLIX CO-ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS No dispute reported 06/30/2026 835053019
Principal investigator 1 Myovant Sciences Inc. $896.45 02/12/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
SPIRIT EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN No dispute reported 06/30/2026 835053021
Principal investigator 1 ABBVIE INC. $974.15 02/04/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792420233
Principal investigator 1 Exeltis, USA Inc. $300.00 02/03/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964383993
Principal investigator 1 Exeltis, USA Inc. $2,125.80 02/02/2021 Non-covered Recipient Entity
Clinical Trials Management
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles No dispute reported 06/30/2026 964383341
Principal investigator 1 Myovant Sciences Inc. $839.03 01/18/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
SPIRIT EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN No dispute reported 06/30/2026 835052789
Principal investigator 1 ABBVIE INC. $863.75 01/05/2021 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792406841